Objective To observe the therapeutic effect of acetylcysteine combined with Bailing capsule on patients with pulmonary fibrosis after COVID-19. Method A total of 106 patients were randomly divided into 2 groups. The control group received conventional treatment with acetylcysteine and routine symptomatic therapy while the experimental group on the basis of the control group' s treatment received Bailing Capsule,2.0 g each time,3 times a day. The total course of treatment was 6 months. Results The experimental group showed statistically significant improvements in lung function and pulmonary fibrosis indicators compared to the control group after treatment,including forced vital capacity (0.60 vs 0.06,P=0.000 ),peak expiratory flow (1.27 vs 0.27,P=0.001),forced expiratory volume in one second (1.17 vs 0.03,P=0.000 ),hyaluronic acid (30.50 vs-17.17,P=0.000 ),laminin (20.00 vs 6.00,P=0.005 ),collagen type Ⅲ protein (10.70 vs-8.30,P=0.000 ) and collagen type Ⅳ protein (16.75 vs 2.10,P=0.049 ). However,there were no significant differences in the improvement of HRCT scores and the effective rate between the 2 groups (P>0.05). The incidence of adverse reactions was also similar in both groups (P>0.05). Conclusion The combination of acetylcysteine and Bailing Capsule in treating pulmonary fibrosis after COVID-19 can improve lung function and pulmonary fibrosis indicators,thus delaying the progression of pulmonary fibrosis.
维普
万方数据